{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:11:39Z","timestamp":1783685499325,"version":"3.55.0"},"reference-count":127,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Until the drugs enter humans life, they may face problems in transportation, drug delivery,\nand metabolism. These problems can cause reducing drug\u2019s therapeutic effect and even increase its side\neffects. Together, these cases can reduce the patient's compliance with the treatment and complicate the\ntreatment process. Much work has been done to solve or at least reduce these problems. For example,\nusing different forms of a single drug molecule (like Citalopram and Escitalopram); slight changes in\nthe drug\u2019s molecule like Meperidine and \u03b1-Prodine, and using carriers (like Tigerase\u00ae). PEGylation is a\nrecently presented method that can use for many targets. Poly Ethylene Glycol or PEG is a polymer that\ncan attach to drugs by using different methods and resulting sustained release, controlled metabolism,\ntargeted delivery, and other cases. Although they will not necessarily lead to an increase in the effect of\nthe drug, they will lead to the improvement of the treatment process in certain ways. In this article, the\nteam of authors has tried to collect and carefully review the best cases based on the PEGylation of drugs\nthat can help the readers of this article.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201820666230621124953","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T08:55:39Z","timestamp":1687424139000},"page":"978-992","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Effect of PEGylation on Drugs\u2019 Pharmacokinetic Parameters; from\nAbsorption to Excretion"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0412-2673","authenticated-orcid":true,"given":"Ali","family":"Khajeei","sequence":"first","affiliation":[{"name":"Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6748-4391","authenticated-orcid":true,"given":"Salar","family":"Masoomzadeh","sequence":"additional","affiliation":[{"name":"Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9714-7257","authenticated-orcid":true,"given":"Tooba","family":"Gholikhani","sequence":"additional","affiliation":[{"name":"Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-3560","authenticated-orcid":true,"given":"Yousef","family":"Javadzadeh","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","volume":"13","author":"D\u2019souza A.A.","year":"2016","unstructured":"D\u2019souza A.A.; Shegokar R.; Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv  2016,13(9),1257-1275","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","volume":"252","author":"Abuchowski A.","year":"1977","unstructured":"Abuchowski A.; van Es T.; Palczuk N.C.; Davis F.F.; Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem  1977,252(11),3578-3581","journal-title":"J Biol Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/jps.2600830432","volume":"83","author":"Yamaoka T.","year":"1994","unstructured":"Yamaoka T.; Tabata Y.; Ikada Y.; Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci  1994,83(4),601-606","journal-title":"J Pharm Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1021\/bc00031a006","volume":"6","author":"Monfardini C.","year":"1995","unstructured":"Monfardini C.; Schiavon O.; Caliceti P.; Morpurgo M.; Harris J.M.; Veronese F.M.; A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem  1995,6(1),62-69","journal-title":"Bioconjug Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrd1033","volume":"2","author":"Harris J.M.","year":"2003","unstructured":"Harris J.M.; Chess R.B.; Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov  2003,2(3),214-221","journal-title":"Nat Rev Drug Discov"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1073\/pnas.94.16.8378","volume":"94","author":"Israelachvili J.","year":"1997","unstructured":"Israelachvili J.; The different faces of poly(ethylene glycol). Proc Natl Acad Sci USA  1997,94(16),8378-8379","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1021\/acsbiomaterials.8b01301","volume":"6","author":"Awad N.S.","year":"2020","unstructured":"Awad N.S.; Paul V.; Mahmoud M.S.; Al Sawaftah N.M.; Kawak P.S.; Al Sayah M.H.; Husseini G.A.; Effect of pegylation and targeting moieties on the ultrasound-mediated drug release from liposomes. ACS Biomater Sci Eng  2020,6(1),48-57","journal-title":"ACS Biomater Sci Eng"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/21691401.2017.1304403","volume":"46","author":"Haghiralsadat F.","year":"2018","unstructured":"Haghiralsadat F.; Amoabediny G.; Helder M.N.; Naderinezhad S.; Sheikhha M.H.; Forouzanfar T.; Zandieh-doulabi B.; A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery. Artif Cells Nanomed Biotechnol  2018,46(1),169-177","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ajps.2015.08.011","volume":"11","author":"Mishra P.","year":"2016","unstructured":"Mishra P.; Nayak B.; Dey R.K.; PEGylation in anti-cancer therapy: An overview. Asian J Pharm Sci  2016,11(3),337-348","journal-title":"Asian J Pharm Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/104345429501200110","volume":"12","author":"Ettinger A.R.","year":"1995","unstructured":"Ettinger A.R.; Pegaspargase (Oncaspar). J Pediatr Oncol Nurs  1995,12(1),46-48","journal-title":"J Pediatr Oncol Nurs"},{"key":"ref=11","first-page":"175","volume":"7","author":"Abuchowski A.","year":"1984","unstructured":"Abuchowski A.; Kazo G.M.; Verhoest C.R.; Van Es T.; Kafkewitz D.; Nucci M.L.; Viau A.T.; Davis F.F.; Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys  1984,7(2),175-186","journal-title":"Cancer Biochem Biophys"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJM198703053161005","volume":"316","author":"Hershfield M.S.","year":"1987","unstructured":"Hershfield M.S.; Buckley R.H.; Greenberg M.L.; Melton A.L.; Schiff R.; Hatem C.; Kurtzberg J.; Markert M.L.; Kobayashi R.H.; Kobayashi A.L.; Abuchowski A.; Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med  1987,316(10),589-596","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.progpolymsci.2012.07.006","volume":"38","author":"Li W.","year":"2013","unstructured":"Li W.; Zhan P.; De Clercq E.; Lou H.; Liu X.; Current drug research on PEGylation with small molecular agents. Prog Polym Sci  2013,38(3-4),421-444","journal-title":"Prog Polym Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14728214.2019.1604684","volume":"24","author":"Park E.J.","year":"2019","unstructured":"Park E.J.; Choi J.; Lee K.C.; Na D.H.; Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs  2019,24(2),107-119","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1021\/ml400370w","volume":"5","author":"Asano S.","year":"2014","unstructured":"Asano S.; Gavrilyuk J.; Burton D.R.; Barbas C.F.; III Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc. ACS Med Chem Lett  2014,5(2),133-137","journal-title":"ACS Med Chem Lett"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1039\/C8OB02535E","volume":"16","author":"Xiao Q.","year":"2018","unstructured":"Xiao Q.; B\u00e9car N.A.; Brown N.P.; Smith M.S.; Stern K.L.; Draper S.R.E.; Thompson K.P.; Price J.L.; Stapling of two PEGylated side chains increases the conformational stability of the WW domain via an entropic effect. Org Biomol Chem  2018,16(46),8933-8939","journal-title":"Org Biomol Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/1120009X.2016.1245235","volume":"29","author":"Verma P.","year":"2017","unstructured":"Verma P.; Dayal S.; Jain V.K.; Amrani A.; Alopecia universalis as a side effect of pegylated interferon \u03b1-ribavirin combination therapy for hepatitis C: A rare case report. J Chemother  2017,29(6),380-382","journal-title":"J Chemother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"15064","DOI":"10.1016\/S0021-9258(18)68146-3","volume":"263","author":"Knauf M.J.","year":"1988","unstructured":"Knauf M.J.; Bell D.P.; Hirtzer P.; Luo Z.P.; Young J.D.; Katre N.V.; Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem  1988,263(29),15064-15070","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","volume":"55","author":"Caliceti P.","year":"2003","unstructured":"Caliceti P.; Veronese F.M.; Pharmacokinetic and biodistribution properties of poly(ethylene glycol)\u2013protein conjugates. Adv Drug Deliv Rev  2003,55(10),1261-1277","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"115306","DOI":"10.1016\/j.bmc.2020.115306","volume":"28","author":"Fu M.","year":"2020","unstructured":"Fu M.; Zhuang X.; Zhang T.; Guan Y.; Meng Q.; Zhang Y.; PEGylated leuprolide with improved pharmacokinetic properties. Bioorg Med Chem  2020,28(4),115306","journal-title":"Bioorg Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0169-409X(93)90005-O","volume":"10","author":"Katre N.V.","year":"1993","unstructured":"Katre N.V.; The conjugation of proteins with polyethylene glycol and other polymers. Adv Drug Deliv Rev  1993,10(1),91-114","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s10529-016-2083-6","volume":"38","author":"Zhou J.Q.","year":"2016","unstructured":"Zhou J.Q.; He T.; Wang J.W.; PEGylation of cytochrome c at the level of lysine residues mediated by a microbial transglutaminase. Biotechnol Lett  2016,38(7),1121-1129","journal-title":"Biotechnol Lett"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1021\/bc300594y","volume":"24","author":"da Silva Freitas D.","year":"2013","unstructured":"da Silva Freitas D.; Mero A.; Pasut G.; Chemical and enzymatic site specific PEGylation of hGH. Bioconjug Chem  2013,24(3),456-463","journal-title":"Bioconjug Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jctb.2507","volume":"86","author":"Gonz\u0644lez-Valdez J.","year":"2011","unstructured":"Gonz\u0644lez-Valdez J.; Cueto L.F.; Benavides J.; Rito-Palomares M.; Potential application of aqueous two-phase systems for the fractionation of RNase A and \u03b1-Lactalbumin from their PEGylated conjugates. J Chem Technol Biotechnol  2011,86(1),26-33","journal-title":"J Chem Technol Biotechnol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","volume":"161","author":"Pasut G.","year":"2012","unstructured":"Pasut G.; Veronese F.M.; State of the art in PEGylation: The great versatility achieved after forty years of research. J Control Release  2012,161(2),461-472","journal-title":"J Control Release"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0169-409X(02)00028-5","volume":"54","author":"Rajender Reddy K.","year":"2002","unstructured":"Rajender Reddy K.; Modi M.W.; Pedder S.; Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev  2002,54(4),571-586","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1046-5928(03)00055-X","volume":"30","author":"Foser S.","year":"2003","unstructured":"Foser S.; Schacher A.; Weyer K.A.; Brugger D.; Dietel E.; Marti S.; Schreitm\u00fcller T.; Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon \u03b1-2a (PEGASYS). Protein Expr Purif  2003,30(1),78-87","journal-title":"Protein Expr Purif"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/mabi.201500282","volume":"16","author":"Grigoletto A.","year":"2016","unstructured":"Grigoletto A.; Mero A.; Zanusso I.; Schiavon O.; Pasut G.; Chemical and Enzymatic Site Specific PEGylation of hGH: The Stability and in vivo Activity of PEG- N -Terminal-hGH and PEG-Gln141-hGH Conjugates. Macromol Biosci  2016,16(1),50-56","journal-title":"Macromol Biosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.foodres.2019.05.038","volume":"123","author":"Luo S.","year":"2019","unstructured":"Luo S.; Lu X.; Liu C.; Zhong J.; Zhou L.; Chen T.; Site specific PEGylation of \u03b2-lactoglobulin at glutamine residues and its influence on conformation and antigenicity. Food Res Int  2019,123,623-630","journal-title":"Food Res Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1381612043452613","volume":"10","author":"Molineux G.","year":"2004","unstructured":"Molineux G.; The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des  2004,10(11),1235-1244","journal-title":"Curr Pharm Des"},{"key":"ref=31","author":"Singh M.","year":"2015","unstructured":"Singh M.; Salnikova M.;  Novel approaches and strategies for biologics, vaccines and cancer therapies  2015","journal-title":"Novel approaches and strategies for biologics, vaccines and cancer therapies"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1021\/acs.biomac.0c01105","volume":"22","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Langley R.J.; Tamshen K.; Harms J.; Middleditch M.J.; Maynard H.D.; Jamieson S.M.F.; Perry J.K.; Enhanced bioactivity of a human GHR antagonist generated by solid-phase site-specific PEGylation. Biomacromolecules  2021,22(2),299-308","journal-title":"Biomacromolecules"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","volume":"54","author":"Roberts M.J.","year":"2002","unstructured":"Roberts M.J.; Bentley M.D.; Harris J.M.; Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev  2002,54(4),459-476","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/088391159701200303","volume":"12","author":"Veronese F.M.","year":"1997","unstructured":"Veronese F.M.; Caliceti P.; Schiavon O.; Branched and linear Poly(Ethylene Glycol): Influence of the Polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J Bioact Compat Polym  1997,12(3),196-207","journal-title":"J Bioact Compat Polym"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1021\/mp200470c","volume":"9","author":"Gokarn Y.R.","year":"2012","unstructured":"Gokarn Y.R.; McLean M.; Laue T.M.; Effect of PEGylation on protein hydrodynamics. Mol Pharm  2012,9(4),762-773","journal-title":"Mol Pharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jconrel.2014.02.002","volume":"180","author":"Pfister D.","year":"2014","unstructured":"Pfister D.; Morbidelli M.; Process for protein PEGylation. J Control Release  2014,180,134-149","journal-title":"J Control Release"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10529-010-0214-z","volume":"32","author":"Constantinou A.","year":"2010","unstructured":"Constantinou A.; Chen C.; Deonarain M.P.; Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol Lett  2010,32(5),609-622","journal-title":"Biotechnol Lett"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1039\/C5SM02668G","volume":"12","author":"Kim J.","year":"2016","unstructured":"Kim J.; Kong Y.P.; Niedzielski S.M.; Singh R.K.; Putnam A.J.; Shikanov A.; Characterization of the crosslinking kinetics of multi-arm poly(ethylene glycol) hydrogels formed via Michael-type addition. Soft Matter  2016,12(7),2076-2085","journal-title":"Soft Matter"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1186\/s12885-015-1672-4","volume":"15","author":"Adkins C.E.","year":"2015","unstructured":"Adkins C.E.; Nounou M.I.; Hye T.; Mohammad A.S.; Terrell-Hall T.; Mohan N.K.; Eldon M.A.; Hoch U.; Lockman P.R.; NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer  2015,15(1),685","journal-title":"BMC Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1002\/cncr.28358","volume":"119","author":"Garrett C.R.","year":"2013","unstructured":"Garrett C.R.; Bekaii-Saab T.S.; Ryan T.; Fisher G.A.; Clive S.; Kavan P.; Shacham-Shmueli E.; Buchbinder A.; Goldberg R.M.; Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer  2013,119(24),4223-4230","journal-title":"Cancer"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"Charych D.H.","year":"2016","unstructured":"Charych D.H.; Hoch U.; Langowski J.L.; Lee S.R.; Addepalli M.K.; Kirk P.B.; Sheng D.; Liu X.; Sims P.W.; VanderVeen L.A.; Ali C.F.; Chang T.K.; Konakova M.; Pena R.L.; Kanhere R.S.; Kirksey Y.M.; Ji C.; Wang Y.; Huang J.; Sweeney T.D.; Kantak S.S.; Doberstein S.K.; NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res  2016,22(3),680-690","journal-title":"Clin Cancer Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1021\/bc00032a002","volume":"6","author":"Zalipsky S.","year":"1995","unstructured":"Zalipsky S.; Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug Chem  1995,6(2),150-165","journal-title":"Bioconjug Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0169-409X(95)00023-Z","volume":"16","author":"Zalipsky S.","year":"1995","unstructured":"Zalipsky S.; Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliv Rev  1995,16(2-3),157-182","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/07366578508081960","volume":"25","author":"Harris J.M.","year":"1985","unstructured":"Harris J.M.; Laboratory synthesis of polyethylene glycol derivatives. J Macromol Sci  1985,25(3),325-373","journal-title":"J Macromol Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1021\/ma00218a005","volume":"23","author":"Dust J.M.","year":"1990","unstructured":"Dust J.M.; Fang Z.H.; Harris J.M.; Proton NMR characterization of poly(ethylene glycols) and derivatives. Macromolecules  1990,23(16),3742-3746","journal-title":"Macromolecules"},{"key":"ref=46","year":"1999","unstructured":"A branched methoxy 40 KDA polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon a-2A (PEGIFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) Available From:  https:\/\/www.natap.org\/2000\/7thcroi\/37rpt22300.html1999"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1021\/bc000082g","volume":"12","author":"Bailon P.","year":"2001","unstructured":"Bailon P.; Palleroni A.; Schaffer C.A.; Spence C.L.; Fung W.J.; Porter J.E.; Ehrlich G.K.; Pan W.; Xu Z.X.; Modi M.W.; Farid A.; Berthold W.; Graves M.; Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon \u03b1-2a for the treatment of hepatitis C. Bioconjug Chem  2001,12(2),195-202","journal-title":"Bioconjug Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","volume":"20","author":"Swierczewska M.","year":"2015","unstructured":"Swierczewska M.; Lee K.C.; Lee S.; What is the future of PEGylated therapies? Expert Opin Emerg Drugs  2015,20(4),531-536","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1134\/S0006350907040124","volume":"52","author":"Metelsky S.T.","year":"2007","unstructured":"Metelsky S.T.; Dependence of the apparent thickness of the unstirred layer at the intestinal mucosa on nutrient concentration. Biophysics  2007,52(4),423-425","journal-title":"Biophysics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10517-021-05330-0","volume":"172","author":"Madonov P.G.","year":"2021","unstructured":"Madonov P.G.; Svyatchenko V.A.; Legostaev S.S.; Kikhtenko N.A.; Kotlyarova A.A.; Oleinik L.A.; Baikalov G.I.; Evaluation of the anti-viral activity of human recombinant interferon Lambda-1 against SARS-CoV-2. Bull Exp Biol Med  2021,172(1),53-56","journal-title":"Bull Exp Biol Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10517-022-05521-3","volume":"173","author":"Sherstoboev E.Y.","year":"2022","unstructured":"Sherstoboev E.Y.; Oleinik L.A.; Zhdanov V.V.; Kikhtenko N.A.; Madonov P.G.; Pharmacokinetic parameters of oral Pegylated IFN-\u03bb1. Bull Exp Biol Med  2022,173(2),215-218","journal-title":"Bull Exp Biol Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"H225","DOI":"10.1111\/j.1750-3841.2009.01274.x","volume":"74","author":"Chan K.","year":"2009","unstructured":"Chan K.; Mong M.; Yin M.; Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and canthaxanthin in nerve growth factor differentiated PC12 cells. J Food Sci  2009,74(7),H225-H231","journal-title":"J Food Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/exd.13437","volume":"27","author":"Park J.H.","year":"2018","unstructured":"Park J.H.; Yeo I.J.; Han J.H.; Suh J.W.; Lee H.P.; Hong J.T.; Anti-inflammatory effect of astaxanthin in phthalic anhydride-induced atopic dermatitis animal model. Exp Dermatol  2018,27(4),378-385","journal-title":"Exp Dermatol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/md10061391","volume":"10","author":"Maoka T.","year":"2012","unstructured":"Maoka T.; Tokuda H.; Suzuki N.; Kato H.; Etoh H.; Anti-oxidative, anti-tumor-promoting, and anti-carcinogensis activities of nitroastaxanthin and nitrolutein, the reaction products of astaxanthin and lutein with peroxynitrite. Mar Drugs  2012,10(12),1391-1399","journal-title":"Mar Drugs"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.3390\/md13074310","volume":"13","author":"Zhang L.","year":"2015","unstructured":"Zhang L.; Wang H.; Multiple mechanisms of anti-cancer effects exerted by Astaxanthin. Mar Drugs  2015,13(7),4310-4330","journal-title":"Mar Drugs"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/jgs.13505","volume":"63","author":"Takemoto M.","year":"2015","unstructured":"Takemoto M.; Yamaga M.; Furuichi Y.; Yokote K.; Astaxanthin improves nonalcoholic fatty liver disease in werner syndrome with diabetes mellitus. J Am Geriatr Soc  2015,63(6),1271-1273","journal-title":"J Am Geriatr Soc"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00011-016-0945-y","volume":"65","author":"Sifi N.","year":"2016","unstructured":"Sifi N.; Martin-Eauclaire M.F.; Laraba-Djebari F.K.; + channel blocker-induced neuroinflammatory response and neurological disorders: Immunomodulatory effects of astaxanthin. Inflamm Res  2016,65(8),623-634","journal-title":"Inflamm Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1039\/C8CC00639C","volume":"54","author":"Li Y.","year":"2018","unstructured":"Li Y.; Kang T.; Wu Y.; Chen Y.; Zhu J.; Gou M.; Carbonate esters turn camptothecin-unsaturated fatty acid prodrugs into nanomedicines for cancer therapy. Chem Commun  2018,54(16),1996-1999","journal-title":"Chem Commun"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1021\/acs.jafc.0c00784","volume":"68","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Yang L.; Guo Y.; Zhang T.; Qiao X.; Wang J.; Xu J.; Xue C.; Hydrophilic Astaxanthin: PEGylated Astaxanthin fights diabetes by enhancing the solubility and oral absorbability. J Agric Food Chem  2020,68(11),3649-3655","journal-title":"J Agric Food Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1208\/s12249-010-9487-8","volume":"11","author":"Kouchakzadeh H.","year":"2010","unstructured":"Kouchakzadeh H.; Shojaosadati S.A.; Maghsoudi A.; Vasheghani Farahani E.; Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology. AAPS PharmSciTech  2010,11(3),1206-1211","journal-title":"AAPS PharmSciTech"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/jbm.a.31343","volume":"84A","author":"Zhang X.","year":"2008","unstructured":"Zhang X.; Pan S.R.; Hu H.M.; Wu G.F.; Feng M.; Zhang W.; Luo X.; Poly(ethylene glycol)-block-polyethylenimine copolymers as carriers for gene delivery: Effects of PEG molecular weight and PEGylation degree. J Biomed Mater Res A  2008,84A(3),795-804","journal-title":"J Biomed Mater Res A"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"10505","DOI":"10.1021\/acsami.8b21609","volume":"11","author":"Tahmasbi Rad A.","year":"2019","unstructured":"Tahmasbi Rad A.; Chen C.W.; Aresh W.; Xia Y.; Lai P.S.; Nieh M.P.; Combinational effects of active targeting, shape, and enhanced permeability and retention for cancer theranostic nanocarriers. ACS Appl Mater Interfaces  2019,11(11),10505-10519","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ijpharm.2019.05.043","volume":"565","author":"Yoshikawa T.","year":"2019","unstructured":"Yoshikawa T.; Mori Y.; Feng H.; Phan K.Q.; Kishimura A.; Kang J.H.; Mori T.; Katayama Y.; Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect. Int J Pharm  2019,565,481-487","journal-title":"Int J Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0162-0134(02)00464-6","volume":"91","author":"Ming L.J.","year":"2002","unstructured":"Ming L.J.; Epperson J.D.; Metal binding and structure\u2013activity relationship of the metalloantibiotic peptide bacitracin. J Inorg Biochem  2002,91(1),46-58","journal-title":"J Inorg Biochem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1099\/00221287-28-3-559","volume":"28","author":"Smith J.L.","year":"1962","unstructured":"Smith J.L.; Weinberg E.D.; Mechanisms of antibacterial action of bacitracin. J Gen Microbiol  1962,28(3),559-569","journal-title":"J Gen Microbiol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1128\/jb.87.5.1044-1050.1964","volume":"87","author":"Hancock R.","year":"1964","unstructured":"Hancock R.; Fitz-James P.C.; Some differences in the action of penicillin, bacitracin, and vancomycin on Bacillus megaterium. J Bacteriol  1964,87(5),1044-1050","journal-title":"J Bacteriol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.2147\/IJN.S136998","volume":"12","author":"Hong W.","year":"2017","unstructured":"Hong W.; Gao X.; Qiu P.; Yang J.; Qiao M.; Shi H.; Zhang D.; Tian C.; Niu S.; Liu M.; Synthesis, construction, and evaluation of self-assembled nano-bacitracin A as an efficient antibacterial agent in vitro and in vivo. Int J Nanomedicine  2017,12,4691-4708","journal-title":"Int J Nanomedicine"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"10688","DOI":"10.1021\/acsami.8b00135","volume":"10","author":"Hong W.","year":"2018","unstructured":"Hong W.; Zhao Y.; Guo Y.; Huang C.; Qiu P.; Zhu J.; Chu C.; Shi H.; Liu M.; PEGylated self-assembled nano-bacitracin A: Probing the antibacterial mechanism and real-time tracing of target delivery in vivo. ACS Appl Mater Interfaces  2018,10(13),10688-10705","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/pharmaceutics11110562","volume":"11","author":"Soe Z.C.","year":"2019","unstructured":"Soe Z.C.; Ou W.; Gautam M.; Poudel K.; Kim B.K.; Pham L.M.; Phung C.D.; Jeong J.H.; Jin S.G.; Choi H.G.; Ku S.K.; Yong C.S.; Kim J.O.; Development of folate-functionalized pegylated zein nanoparticles for ligand-directed delivery of paclitaxel. Pharmaceutics  2019,11(11),562","journal-title":"Pharmaceutics"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijpharm.2011.12.058","volume":"424","author":"Zeng N.","year":"2012","unstructured":"Zeng N.; Hu Q.; Liu Z.; Gao X.; Hu R.; Song Q.; Gu G.; Xia H.; Yao L.; Pang Z.; Jiang X.; Chen J.; Fang L.; Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. Int J Pharm  2012,424(1-2),58-66","journal-title":"Int J Pharm"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12272-020-01218-1","volume":"43","author":"Phung C.D.","year":"2020","unstructured":"Phung C.D.; Tran T.H.; Kim J.O.; Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: A review. Arch Pharm Res  2020,43(1),32-45","journal-title":"Arch Pharm Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40005-019-00448-w","volume":"50","author":"Cho H.J.","year":"2020","unstructured":"Cho H.J.; Recent progresses in the development of hyaluronic acid-based nanosystems for tumor-targeted drug delivery and cancer imaging. J Pharm Investig  2020,50(2),115-129","journal-title":"J Pharm Investig"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1080\/03639045.2017.1357729","volume":"43","author":"Tran B.N.","year":"2017","unstructured":"Tran B.N.; Nguyen H.T.; Kim J.O.; Yong C.S.; Nguyen C.N.; Developing combination of artesunate with paclitaxel loaded into poly- D,L -lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response. Drug Dev Ind Pharm  2017,43(12),1952-1962","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=74","first-page":"1549","volume":"31","author":"Aung W.","year":"2011","unstructured":"Aung W.; Sogawa C.; Furukawa T.; Saga T.; Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. Anticancer Res  2011,31(5),1549-1558","journal-title":"Anticancer Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1538-7445.AM2014-470","volume":"74","author":"Chen Y.","year":"2014","unstructured":"Chen Y.; Chin B.W.; Bieber M.M.; Tan X.; Teng N.N.; Abstract 470: Artemisinin derivatives synergize with paclitaxel by targeting FOXM1 through Raf\/MEK\/MAPK signaling pathway in ovarian cancer. Cancer Res  2014,74,470-470","journal-title":"Cancer Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/02652048.2015.1114042","volume":"33","author":"Wang L.","year":"2016","unstructured":"Wang L.; Wang Y.; Wang X.; Sun L.; Zhou Z.; Lu J.; Zheng Y.; Encapsulation of low lipophilic and slightly water-soluble dihydroartemisinin in PLGA nanoparticles with phospholipid to enhance encapsulation efficiency and in vitro bioactivity. J Microencapsul  2016,33(1),43-52","journal-title":"J Microencapsul"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11095-020-02819-7","volume":"37","author":"Phung C.D.","year":"2020","unstructured":"Phung C.D.; Le T.G.; Nguyen V.H.; Vu T.T.; Nguyen H.Q.; Kim J.O.; Yong C.S.; Nguyen C.N.; PEGylated-Paclitaxel and dihydroartemisinin nanoparticles for simultaneously delivering paclitaxel and dihydroartemisinin to colorectal cancer. Pharm Res  2020,37(7),129","journal-title":"Pharm Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-biophys-083012-130404","volume":"42","author":"Wilson R.C.","year":"2013","unstructured":"Wilson R.C.; Doudna J.A.; Molecular mechanisms of RNA interference. Annu Rev Biophys  2013,42(1),217-239","journal-title":"Annu Rev Biophys"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10555-017-9717-6","volume":"37","author":"Chen X.","year":"2018","unstructured":"Chen X.; Mangala L.S.; Rodriguez-Aguayo C.; Kong X.; Lopez-Berestein G.; Sood A.K.; RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev  2018,37(1),107-124","journal-title":"Cancer Metastasis Rev"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.biomaterials.2015.11.056","volume":"79","author":"Xia Y.","year":"2016","unstructured":"Xia Y.; Tian J.; Chen X.; Effect of surface properties on liposomal siRNA delivery. Biomaterials  2016,79,56-68","journal-title":"Biomaterials"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1248\/bpb.b13-00059","volume":"36","author":"Hatakeyama H.","year":"2013","unstructured":"Hatakeyama H.; Akita H.; Harashima H.; The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull  2013,36(6),892-899","journal-title":"Biol Pharm Bull"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.3892\/mmr.2020.11525","volume":"22","author":"Hattori Y.","year":"2020","unstructured":"Hattori Y.; Tamaki K.; Sakasai S.; Ozaki K.I.; Onishi H.; Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene silencing effects and siRNA biodistribution in mice. Mol Med Rep  2020,22(5),4183-4196","journal-title":"Mol Med Rep"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1517\/17425255.2014.967679","volume":"10","author":"Zhang X.","year":"2014","unstructured":"Zhang X.; Wang H.; Ma Z.; Wu B.; Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Expert Opin Drug Metab Toxicol  2014,10(12),1691-1702","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1021\/acs.jmedchem.0c01774","volume":"64","author":"Hoguet V.","year":"2021","unstructured":"Hoguet V.; Lasalle M.; Maingot M.; Dequirez G.; Boulahjar R.; Leroux F.; Piveteau C.; Herledan A.; Biela A.; Dumont J.; Ch\u0644vez-Talavera O.; Belloy L.; Duplan I.; Hennuyer N.; Butruille L.; Lestavel S.; Sevin E.; Culot M.; Gosselet F.; Staels B.; Deprez B.; Tailleux A.; Charton J.; Beyond the rule of 5: Impact of PEGylation with various polymer sizes on pharmacokinetic properties, structure\u2013properties relationships of mPEGylated small agonists of TGR5 receptor. J Med Chem  2021,64(3),1593-1610","journal-title":"J Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1080\/21691401.2017.1347880","volume":"46","author":"Manjili H.K.","year":"2018","unstructured":"Manjili H.K.; Malvandi H.; Mousavi M.S.; Attari E.; Danafar H.; In vitro and in vivo delivery of artemisinin loaded PCL\u2013PEG\u2013PCL micelles and its pharmacokinetic study. Artif Cells Nanomed Biotechnol  2018,46(5),926-936","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1177391X0800200003","volume":"2","author":"Lu X.","year":"2008","unstructured":"Lu X.; Lu D.; Scully M.; Kakkar V.; The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem  2008,2,57-73","journal-title":"Perspect Medicin Chem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1002\/ijc.28267","volume":"133","author":"Vogetseder A.","year":"2013","unstructured":"Vogetseder A.; Thies S.; Ingold B.; Roth P.; Weller M.; Schraml P.; Goodman S.L.; Moch H.; \u03b1v-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer  2013,133(10),2362-2371","journal-title":"Int J Cancer"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2174\/138945009788680374","volume":"10","author":"Bandyopadhyay A.","year":"2009","unstructured":"Bandyopadhyay A.; Raghavan S.; Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets  2009,10(7),645-652","journal-title":"Curr Drug Targets"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-11-1116","volume":"18","author":"Kimura R.H.","year":"2012","unstructured":"Kimura R.H.; Teed R.; Hackel B.J.; Pysz M.A.; Chuang C.Z.; Sathirachinda A.; Willmann J.K.; Gambhir S.S.; Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res  2012,18(3),839-849","journal-title":"Clin Cancer Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1158\/0008-5472.CAN-08-4410","volume":"69","author":"Hausner S.H.","year":"2009","unstructured":"Hausner S.H.; Abbey C.K.; Bold R.J.; Gagnon M.K.; Marik J.; Marshall J.F.; Stanecki C.E.; Sutcliffe J.L.; Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res  2009,69(14),5843-5850","journal-title":"Cancer Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2967\/jnumed.114.150680","volume":"56","author":"Hausner S.H.","year":"2015","unstructured":"Hausner S.H.; Bauer N.; Hu L.Y.; Knight L.M.; Sutcliffe J.L.; The effect of Bi-Terminal PEGylation of an integrin \u03b1 v \u03b2 6 \u2013Targeted 18 F peptide on pharmacokinetics and tumor uptake. J Nucl Med  2015,56(5),784-790","journal-title":"J Nucl Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"592294","DOI":"10.3389\/fbioe.2020.592294","volume":"8","author":"Xu J.","year":"2020","unstructured":"Xu J.; Sun T.; Zhong R.; You C.; Tian M.; PEGylation of deferoxamine for improving the stability, cytotoxicity, and iron-overload in an experimental stroke model in rats. Front Bioeng Biotechnol  2020,8,592294","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22541\/au.158870115.54235041","author":"Sun J.","year":"2020","unstructured":"Sun J.; Wu J.; Jin H.; Ying T.; Jin W.; Fan M.; Zhou J.; Chen H.; Jin L.; Zhou J.; Structure-guided PEGylated fibroblast growth factor 2 variants accelerate wound healing with improved stability. Authorea  2020,1-18","journal-title":"Authorea"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1524-475X.2002.10903.x","volume":"10","author":"Ladwig G.P.","year":"2002","unstructured":"Ladwig G.P.; Robson M.C.; Liu R.; Kuhn M.A.; Muir D.F.; Schultz G.S.; Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen  2002,10(1),26-37","journal-title":"Wound Repair Regen"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.colsurfb.2018.09.006","volume":"172","author":"Xu H.L.","year":"2018","unstructured":"Xu H.L.; Chen P.P.; Wang L.F.; Tong M.Q.; Ou Z.; Zhao Y.Z.; Xiao J.; Fu T.L.; Wei-Xue, Skin-permeable liposome improved stability and permeability of bFGF against skin of mice with deep second degree scald to promote hair follicle neogenesis through inhibition of scar formation. Colloids Surf B Biointerfaces  2018,172,573-585","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jddst.2018.09.009","volume":"49","author":"Peng G.","year":"2019","unstructured":"Peng G.; Pan X.; Hu H.; Xu Y.; Wu C.; N-terminal site-specific PEGylation enhances the circulation half-life of Thymosin alpha 1. J Drug Deliv Sci Technol  2019,49,405-412","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1080\/10717544.2022.2100511","volume":"29","author":"Seo H.","year":"2022","unstructured":"Seo H.; Bae H.D.; Pyun H.; Kim B.G.; Lee S.I.; Song J.S.; Lee K.; PEGylation improves the therapeutic potential of dimerized translationally controlled tumor protein blocking peptide in ovalbumin-induced mouse model of airway inflammation. Drug Deliv  2022,29(1),2320-2329","journal-title":"Drug Deliv"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11095-018-2412-7","volume":"35","author":"Zbyszynski P.","year":"2018","unstructured":"Zbyszynski P.; Tomasini-Johansson B.R.; Peters D.M.; Kwon G.S.; Characterization of the PEGylated Functional Upstream Domain Peptide (PEG-FUD): A potent fibronectin assembly inhibitor with potential as an anti-fibrotic therapeutic. Pharm Res  2018,35(7),126","journal-title":"Pharm Res"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/ajhp\/54.2.162","volume":"54","author":"Hui Y.F.","year":"1997","unstructured":"Hui Y.F.; Reitz J.; Gemcitabine: A cytidine analogue active against solid tumors. Am J Health Syst Pharm  1997,54(2),162-170","journal-title":"Am J Health Syst Pharm"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trsl.2018.12.008","volume":"207","author":"Abdalla M.Y.","year":"2019","unstructured":"Abdalla M.Y.; Ahmad I.M.; Rachagani S.; Banerjee K.; Thompson C.M.; Maurer H.C.; Olive K.P.; Bailey K.L.; Britigan B.E.; Kumar S.; Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition. Transl Res  2019,207,56-69","journal-title":"Transl Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00002820-199904000-00011","volume":"22","author":"Barton-Burke M.","year":"1999","unstructured":"Barton-Burke M.; Gemcitabine: A pharmacologic and clinical overview. Cancer Nurs  1999,22(2),176-183","journal-title":"Cancer Nurs"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.3816\/CLC.2003.s.005","volume":"4","author":"Chiappori A.A.","year":"2003","unstructured":"Chiappori A.A.; Rocha-Lima C.M.; New agents in the treatment of small-cell lung cancer: Focus on gemcitabine. Clin Lung Cancer  2003,4(Suppl. 2),S56-S63","journal-title":"Clin Lung Cancer"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jpba.2017.12.048","volume":"151","author":"van Nuland M.","year":"2018","unstructured":"van Nuland M.; Hillebrand M.J.X.; Rosing H.; Burgers J.A.; Schellens J.H.M.; Beijnen J.H.; Ultra-sensitive LC\u2013MS\/MS method for the quantification of gemcitabine and its metabolite 2\u20322\u2032-difluorodeoxyuridine in human plasma for a microdose clinical trial. J Pharm Biomed Anal  2018,151,25-31","journal-title":"J Pharm Biomed Anal"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jchromb.2003.11.038","volume":"802","author":"Xu Y.","year":"2004","unstructured":"Xu Y.; Keith B.; Grem J.L.; Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci  2004,802(2),263-270","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=105","first-page":"S7-2-S7","volume":"24","author":"Storniolo A.M.","year":"1997","unstructured":"Storniolo A.M.; Allerheiligen S.R.; Pearce H.L.; Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol  1997,24(2 Suppl 7),S7-2-S7-7","journal-title":"Semin Oncol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1023\/A:1025415616592","volume":"48","author":"Robinson K.","year":"2003","unstructured":"Robinson K.; Lambiase L.; Li J.; Monteiro C.; Schiff M.; Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci  2003,48(9),1804-1808","journal-title":"Dig Dis Sci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"120184","DOI":"10.1016\/j.talanta.2019.120184","volume":"206","author":"Yin L.","year":"2020","unstructured":"Yin L.; Ren T.; Zhao S.; Shi M.; Gu J.; Comparative pharmacokinetic study of PEGylated gemcitabine and gemcitabine in rats by LC-MS\/MS coupled with pre-column derivatization and MSALL technique. Talanta  2020,206,120184","journal-title":"Talanta"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1471-2407-11-183","volume":"11","author":"Liu J.","year":"2011","unstructured":"Liu J.; Zhang Y.; Qu J.; Xu L.; Hou K.; Zhang J.; Qu X.; Liu Y.; \u03b2-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer  2011,11(1),183","journal-title":"BMC Cancer"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1211\/jpp.61.12.0010","volume":"61","author":"Wu X.S.","year":"2010","unstructured":"Wu X.S.; Xie T.; Lin J.; Fan H.Z.; Huang-Fu H.J.; Ni L.F.; Yan H.F.; An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas. J Pharm Pharmacol  2010,61(12),1653-1656","journal-title":"J Pharm Pharmacol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1142\/S0192415X11009421","volume":"39","author":"Chen M.","year":"2011","unstructured":"Chen M.; Wang S.; Tan M.; Wang Y.; Applications of nanoparticles in herbal medicine: Zedoary turmeric oil and its active compound \u03b2-elemene. Am J Chin Med  2011,39(6),1093-1102","journal-title":"Am J Chin Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"60","DOI":"10.20892\/j.issn.2095-3941.2019.0156","volume":"17","author":"Zhai B.","year":"2020","unstructured":"Zhai B.; Wu Q.; Wang W.; Zhang M.; Han X.; Li Q.; Chen P.; Chen X.; Huang X.; Li G.; Zhang Q.; Zhang R.; Xiang Y.; Liu S.; Duan T.; Lou J.; Xie T.; Sui X.; Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated \u03b2-elemene liposomes. Cancer Biol Med  2020,17(1),60-75","journal-title":"Cancer Biol Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"Srivastava A.","year":"2013","unstructured":"Srivastava A.; Brewer A.K.; Mauser-Bunschoten E.P.; Key N.S.; Kitchen S.; Llinas A.; Ludlam C.A.; Mahlangu J.N.; Mulder K.; Poon M.C.; Street A.; Guidelines for the management of hemophilia. Haemophilia  2013,19(1),e1-e47","journal-title":"Haemophilia"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","volume":"9","author":"Gringeri A.","year":"2011","unstructured":"Gringeri A.; Lundin B.; Von MacKensen S.; Mantovani L.; Mannucci P.M.; A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost  2011,9(4),700-710","journal-title":"J Thromb Haemost"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"Manco-Johnson M.J.","year":"2007","unstructured":"Manco-Johnson M.J.; Abshire T.C.; Shapiro A.D.; Riske B.; Hacker M.R.; Kilcoyne R.; Ingram J.D.; Manco-Johnson M.L.; Funk S.; Jacobson L.; Valentino L.A.; Hoots W.K.; Buchanan G.R.; DiMichele D.; Recht M.; Brown D.; Leissinger C.; Bleak S.; Cohen A.; Mathew P.; Matsunaga A.; Medeiros D.; Nugent D.; Thomas G.A.; Thompson A.A.; McRedmond K.; Soucie J.M.; Austin H.; Evatt B.L.; Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med  2007,357(6),535-544","journal-title":"N Engl J Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","volume":"7","author":"Collins P.W.","year":"2009","unstructured":"Collins P.W.; Blanchette V.S.; Fischer K.; Bj\u0650rkman S.; Oh M.; Fritsch S.; Schroth P.; Spotts G.; Astermark J.; Ewenstein B.; Break\u2010through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost  2009,7(3),413-420","journal-title":"J Thromb Haemost"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","volume":"116","author":"Mei B.","year":"2010","unstructured":"Mei B.; Pan C.; Jiang H.; Tjandra H.; Strauss J.; Chen Y.; Liu T.; Zhang X.; Severs J.; Newgren J.; Chen J.; Gu J.M.; Subramanyam B.; Fournel M.A.; Pierce G.F.; Murphy J.E.; Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood  2010,116(2),270-279","journal-title":"Blood"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1021\/bc990137i","volume":"11","author":"R\u00f6stin J.","year":"2000","unstructured":"R\u00f6stin J.; Smeds A.L.; \u00c5kerblom E.; B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconjug Chem  2000,11(3),387-396","journal-title":"Bioconjug Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00277-019-03747-2","volume":"98","author":"Shah A.","year":"2019","unstructured":"Shah A.; Solms A.; Wiegmann S.; Ahsman M.; Berntorp E.; Tiede A.; Iorio A.; Mancuso M.E.; Zhivkov T.; Lissitchkov T.; Direct comparison of two extended-half-life recombinant FVIII products: A randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol  2019,98(9),2035-2044","journal-title":"Ann Hematol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.apsb.2020.04.011","volume":"10","author":"Yu J.","year":"2020","unstructured":"Yu J.; Wang Y.; Zhou S.; Li J.; Wang J.; Chi D.; Wang X.; Lin G.; He Z.; Wang Y.; Remote loading paclitaxel\u2013doxorubicin prodrug into liposomes for cancer combination therapy. Acta Pharm Sin B  2020,10(9),1730-1740","journal-title":"Acta Pharm Sin B"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"14577","DOI":"10.1021\/acsami.1c00184","volume":"13","author":"Zhao J.","year":"2021","unstructured":"Zhao J.; Du J.; Wang J.; An N.; Zhou K.; Hu X.; Dong Z.; Liu Y.; Folic Acid and Poly(ethylene glycol) decorated paclitaxel nanocrystals exhibit enhanced stability and breast cancer-targeting capability. ACS Appl Mater Interfaces  2021,13(12),14577-14586","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1166\/jbn.2014.1743","volume":"10","author":"Coelho S.C.","year":"2014","unstructured":"Coelho S.C.; Rocha S.; Pereira M.C.; Juzenas P.; Coelho M.A.N.; Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles. J Biomed Nanotechnol  2014,10(4),717-723","journal-title":"J Biomed Nanotechnol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0142-9612(02)00445-3","volume":"24","author":"Fischer D.","year":"2003","unstructured":"Fischer D.; Li Y.; Ahlemeyer B.; Krieglstein J.; Kissel T.; In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials  2003,24(7),1121-1131","journal-title":"Biomaterials"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1021\/bc060077y","volume":"17","author":"Hong S.","year":"2006","unstructured":"Hong S.; Leroueil P.R.; Janus E.K.; Peters J.L.; Kober M.M.; Islam M.T.; Orr B.G.; Baker J.R.; Banaszak Holl M.M.; Interaction of polycationic polymers with supported lipid bilayers and cells: Nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem  2006,17(3),728-734","journal-title":"Bioconjug Chem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"119389","DOI":"10.1016\/j.ijpharm.2020.119389","volume":"584","author":"Sahoo R.K.","year":"2020","unstructured":"Sahoo R.K.; Gothwal A.; Rani S.; Nakhate K.T.; Ajazuddin ; Gupta U.; PEGylated dendrimer mediated delivery of bortezomib: Drug conjugation versus encapsulation. Int J Pharm  2020,584,119389","journal-title":"Int J Pharm"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"110375","DOI":"10.1016\/j.msec.2019.110375","volume":"108","author":"Mukherjee S.","year":"2020","unstructured":"Mukherjee S.; Kotcherlakota R.; Haque S.; Bhattacharya D.; Kumar J.M.; Chakravarty S.; Patra C.R.; Improved delivery of doxorubicin using rationally designed PEGylated platinum nanoparticles for the treatment of melanoma. Mater Sci Eng C  2020,108,110375","journal-title":"Mater Sci Eng C"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1021\/acsbiomaterials.9b01693","volume":"6","author":"Mukherjee S.","year":"2020","unstructured":"Mukherjee S.; Kotcherlakota R.; Haque S.; Das S.; Nuthi S.; Bhattacharya D.; Madhusudana K.; Chakravarty S.; Sistla R.; Patra C.R.; Silver prussian blue analogue nanoparticles: Rationally designed advanced nanomedicine for multifunctional biomedical applications. ACS Biomater Sci Eng  2020,6(1),690-704","journal-title":"ACS Biomater Sci Eng"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2000082","DOI":"10.1002\/anbr.202000082","volume":"1","author":"Mukherjee S.","year":"2021","unstructured":"Mukherjee S.; Bollu V.S.; Roy A.; Nethi S.K.; Madhusudana K.; Kumar J.M.; Sistla R.; Patra C.R.; Acute toxicity, biodistribution, and pharmacokinetics studies of Pegylated Platinum Nanoparticles in mouse model. Adv NanoBiomed Res  2021,1(7),2000082","journal-title":"Adv NanoBiomed Res"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201820666230621124953","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/218135\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201820666230621124953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T17:10:39Z","timestamp":1713978639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/218135\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":127,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201820666230621124953","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}